Trade Analytics

Sun Pharma

Go Back

Sun Pharma

  • Among the top five Indian pharma companies
  • Strong presence in generics market
  • 23 manufacturing sites worldwide
  • Over half the sales from North America
  • Revenue base of about US$ 2.6 billion in FY14

Sun Pharmaceutical Industries Ltd is an international specialty pharma company. The Company manufactures and markets pharmaceuticals formulations as branded generics, as well as generics in India, the United States (US) and several other markets across the world.

The Company’s business is divided into four segments: Indian Branded Generics, US Generics, International Branded Generics (ROW) and Active Pharmaceutical Ingredients (API).

Its brands are prescribed in chronic therapy areas like cardiology, psychiatry, neurology, gastroenterology, diabetology and respiratory. It makes specialty APIs, including peptides, steroids, hormones and anticancers. APIs and Dosage forms are made at 20 plants across India, Israel, the US, Canada, Hungary, Brazil, Mexico and Bangladesh. Its API products include Acamprosate Calcium, Alendronate Sodium, Amifostine trihydrate, Budensonide and Carvedilol.

In September 2010, it acquired Taro Pharmaceutical industries Ltd.


Sun Pharma: Leveraging its generic market capabilities

2010 Acquired controlling stake in Israel-based Taro Pharmaceuticals, effectively doubling the company’s US business.
2000 Became the fifth largest Indian pharmaceutical company
1995 First API manufacturing plant was built in Panoli, Gujarat
1991 Established its first research centre
1983 Commenced operations in Kolkata

Updated: December, 2014

Research and Development
India is presently ranked 76th among a total of 143 economies, as per the Global Innovation Index (GII).
x IBEF : India Brand Equity Foundation